Skye Bioscience, Inc. (SKYE)

Skye Bioscience Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	165	-	-	-	-	-
Enterprise Value	78	-6	1	-7	-1	-1
PB Ratio	2.10	-	-	-	-	-
EV/EBITDA Ratio	2.43	0.16	-0.04	0.89	0.17	-0.70
EV/EBIT Ratio	2.42	0.16	-0.04	0.88	0.17	-0.70
EV/FCF Ratio	5.99	0.41	-0.05	1.04	0.16	0.24
Debt / Equity Ratio	0.06	-2.16	-0.64	0.36	3.32	0.71
Debt / EBITDA Ratio	-0.13	-0.13	-0.10	-0.28	-0.26	0.19
Debt / FCF Ratio	-0.33	-0.33	-0.15	-0.33	-0.25	-0.06
Quick Ratio	5.85	0.74	0.10	2.30	3.14	1.89
Current Ratio	5.99	0.84	0.74	2.46	3.39	2.06
Interest Coverage	-27.30	-40.53	-28.28	-10.08	-8.29	2.05
Return on Equity (ROE)	-212.30%	1157.70%	2151.60%	-180.60%	1052.60%	-7.60%
Return on Assets (ROA)	-120.40%	-438.10%	-322.60%	-105.10%	-331.30%	36.50%
Return on Capital (ROIC)	-45.14%	-1398.67%	1694.00%	-98.09%	-322.75%	-708.19%
Earnings Yield	-22.68%	-	-	-	-	-
FCF Yield	-8.84%	-	-	-	-	-
Buyback Yield / Dilution	-643.18%	-215.43%	-36.56%	-75.70%	-36.48%	-39.95%
Total Shareholder Return	-643.18%	-215.43%	-36.56%	-75.70%	-36.48%	-39.95%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).